

CITATION REPORT

List of articles citing

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

DOI: 10.1053/j.seminoncol.2003.08.013
Seminars in Oncology, 2003, 30, 117-24.

Source: <https://exaly.com/paper-pdf/34992276/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
428	Bevacizumab in the treatment of breast cancer: rationale and current data. 2004 , 9 Suppl 1, 43-9		75
427	Maximizing the potential of bevacizumab in cancer treatment. 2004 , 9 Suppl 1, 36-42		64
426	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. 2004 , 3, 391-400		1872
425	Angiogenic growth factors and hypertension. 2004 , 7, 193-201		179
424	Molecular targeting of angiogenesis for imaging and therapy. 2004 , 31, 1327-41		29
423	Targeted Therapies for Cancer 2004. 2004 , 122, 598-609		220
422	Angiogenesis in colorectal cancer: therapeutic implications and future directions. 2004 , 18, 1087-119, ix		5
421	Vascular endothelial growth factor antagonists as anticancer agents. 2004 , 3, 229-245		
420	Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?. 2004 , 6, 128-32		18
419	Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. 2004 , 109, 3122-31		560
418	Molecularly targeted therapies for breast cancer. 2005 , 12, 73-81		30
417	Physiologic aspects of aging: impact on cancer management and decision making, part I. 2005 , 11, 449-60		135
416	Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. 2005 , 23, 1011-27		2248
415	The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. 2005 , 128, 303-9		143
414	Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). 2005 , 114, 224-9		42
413	Clinical trials: bad combinations or bad designs. 2005 , 7, 419-20		
412	Strategies and methodologies for identifying molecular targets in sarcomas and other tumors. 2005 , 6, 487-97		5

411	Bevacizumab in combination chemotherapy for colorectal and other cancers. 2005 , 62, 1021-32	42
410	Molecularly Targeted Therapy for Thyroid Cancer. 2005 , 20, 105	1
409	Extending survival with chemotherapy in metastatic breast cancer. 2005 , 10 Suppl 3, 20-9	454
408	A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. 2005 , 11, 3369-76	172
407	VEGF-targeted therapy: therapeutic potential and recent advances. 2005 , 10, 382-91	113
406	Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. 2005 , 23, 792-9	1151
405	ZD6474--clinical experience to date. 2005 , 92 Suppl 1, S14-20	55
404	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. 2005 , 23, 2544-55	497
403	A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs. 2005 , 11, 7589-92	13
402	Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer. 2005 , 1, 51-61	1
401	Managing patients treated with bevacizumab combination therapy. 2005 , 69 Suppl 3, 25-33	232
400	The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. 2005 , 7, 486-96	26
399	Angiogenesis and lung cancer: prognostic and therapeutic implications. 2005 , 23, 3243-56	207
398	Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. 2005 , 69 Suppl 3, 46-56	75
397	Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. 2005 , 307, 58-62	4088
396	Bevacizumab. 2006 , 5, 43-60	18
395	Breast Cancer and Molecular Medicine. 2006 ,	2
394	Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. 2006 , 20, 193-5	22

393	The safety of bevacizumab. 2006 , 5, 289-301		28
392	Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. 2006 , 66, 1577-91		51
391	Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. 2006 , 28, 1779-802		392
390	Breast cancer. 2006 , 1, 187-210		2
389	Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents. 2006 , 1, 159-173		4
388	Biomolecular markers of breast cancer. 2006 , 11, 1818-43		51
387	Nuove vie di trattamento del carcinoma del colon-retto: Dalla chemioterapia orale agli inibitori dell'angiogenesi. 2006 , 92, 1-15		
386	Monoclonal Antibody Therapy of Cancer. 2006 , 487-502		
385	Systemic treatments for inflammatory breast cancer. 2005 , 22, 55-65		13
384	Tumor metastasis: mechanistic insights and clinical challenges. 2006 , 12, 895-904		1588
383	Targeting VEGF in cancer therapy. 2006 , 30, 7-32		23
382	HER-2/neu Cancer Vaccines: Present Status and Future Prospects. 2006 , 12, 65-77		4
381	Anticorps anti-VEGF: un emploi universel?. 2006 , 8, 808-814		
380	[Treatment of breast cancer: from hormones to antibodies]. 2006 , 47, 1223-4, 1226-8		
379	Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. <i>Seminars in Oncology</i> , 2006 , 33, S41-9	5.5	12
378	Development of antibody-based therapeutics for oncology indications. 2006 , 67, 699-728		2
377	Biological agents versus chemotherapy in the treatment of colorectal cancer. 2006 , 7, 1251-71		2
376	Emerging drugs to replace current leaders in first-line therapy for breast cancer. 2006 , 11, 489-501		11

375	Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. 2006 , 12, 3124-9	108
374	Inhibitors of signal transduction protein kinases as targets for cancer therapy. 2006 , 12, 153-223	17
373	Handbook of Metastatic Breast Cancer. 2006 ,	15
372	PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. 2006 , 5, 37-43	47
371	Primary systemic therapy on local advance breast cancer, where are we going?. 2006 , 17 Suppl 7, vii18-21	2
370	A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. 2006 , 17, 1320-7	39
369	Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. 2006 , 223-68	49
368	Second-line treatment of postmenopausal women with advanced breast carcinoma. 2006 , 6, 613-24	
367	Anti-VEGF therapy: a new approach to colorectal cancer therapy. 2006 , 6, 1385-96	13
366	Antiangiogenic agents in breast cancer. 2007 , 25, 518-26	12
365	Transcatheter and ablative therapeutic approaches for solid malignancies. 2007 , 25, 978-86	148
364	Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 2007 , 13, 1253-9	896
363	Bevacizumab in the management of solid tumors. 2007 , 7, 433-45	42
362	From the trastuzumab era to new target therapies: beyond revolution. 2007 , 18 Suppl 6, vi1-4	7
361	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. 2007 , 292, C987-95	251
360	Targeted therapy of breast cancer. 2007 , 13, 497-517	24
359	Conditionally replicating adenoviruses for cancer treatment. 2007 , 7, 285-301	39
358	Therapieoptionen für Patientinnen mit metastasiertem Mammakarzinom nach vorangegangener Anthrazyklin- und Taxanbehandlung. 2007 , 67, 1311-1316	

357	Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. 2007 , 6, 1691-9	147
356	Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. 2007 , 36, 3-23	34
355	Design of clinical trials of radiation combined with antiangiogenic therapy. 2007 , 12, 465-77	78
354	Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. 2007 , 12, 375-89	27
353	Shortening the infusion time of anticancer drugs: who will benefit?. 2007 , 25, 2642-3	1
352	Bevacizumab (Avastin). 2008 , 779-812	
351	Optimal Biological Dose for Molecularly-Targeted Therapies. 2007 , 1	1
350	Bevacizumab in the Treatment of Metastatic Breast Cancer. 2007 , 2, 82-88	4
349	Pharmacology of Epidermal Growth Factor Inhibitors. 2007 , 22, 24-39	9
348	Novel approaches to advanced breast cancer: bevacizumab and lapatinib. 2007 , 5, 314-23	12
347	Adjuvant biologic therapy for breast cancer. 2007 , 13, 156-61	2
346	Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). 2007 ,	1
345	Targeting metastatic and advanced breast cancer. 2007 , 23, 37-45	7
344	Molecular targeted therapies in breast cancer: where are we now?. 2007 , 39, 1375-87	29
343	VEGF/VEGFR signalling as a target for inhibiting angiogenesis. 2007 , 16, 83-107	138
342	Drug insight: VEGF as a therapeutic target for breast cancer. 2007 , 4, 181-9	83
341	Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. 2007 , 25, 5180-6	626
340	Targeting angiogenesis in advanced breast cancer. 2007 , 21, 209-14	10

339	Challenges in the Management of Metastatic Breast Cancer. 2007 , 10, 128-133	
338	Bevacizumab for advanced breast cancer. 2007 , 21, 303-19	22
337	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. 2007 , 5, 203-20	323
336	Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles. 2007 , 67, 1800-1	
335	Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. 2007 , 7, 779-83	27
334	The direct effects of anti-vascular endothelial growth factor therapy on tumor cells. 2007 , 6, 564-71	7
333	Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. 2007 , 120, 278-84	24
332	Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. 2007 , 121, 2606-14	58
331	Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. 2007 , 64, 115-28	25
330	Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. 2007 , 7, 475-85	418
329	Angiogenesis as targeted breast cancer therapy. 2007 , 16 Suppl 2, S17-9	39
328	[Bevacizumab-induced serious heart failure in a patient treated with anthracyclines]. 2007 , 31, 256-7	2
327	S9 Blocking crosstalk between ER and growth factor receptors to circumvent endocrine resistance. 2007 , 16, S2-S3	
326	S10 Inflammation and breast cancer: Hypothesis for targeted therapies. 2007 , 16, S3	1
325	S11 Angiogenesis as targeted breast cancer therapy. 2007 , 16, S3	
324	S12 Immunity and breast cancer cells: Role of vaccination. 2007 , 16, S3-S4	
323	Vascular endothelial growth factor and bevacitumab in breast cancer. 2007 , 14, 163-73	33
322	Mechanisms of disease: angiogenesis and the management of breast cancer. 2007 , 4, 536-50	93

321	Taxanes in breast cancer: an update. 2007 , 9, 22-30	40
320	Current status of signal transduction modulators in the treatment of gynecologic malignancies. 2007 , 8, 383-92	5
319	New multitargeted treatments with antiangiogenic and antitumor activity: focus on sunitinib. 2007 , 2, 17-29	
318	VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. 2007 , 2, 153-164	8
317	Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. 2008 , 107, 133-8	86
316	Research progress in the use of drugs for breast cancer targeted therapy. 2008 , 5, 320-325	
315	Neurologic complications of antitumor antibody therapies. 2008 , 8, 259-63	3
314	Angiogenesis as a therapeutic target in advanced breast cancer. 2008 , 1, 9-12	1
313	Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. 2008 , 15, 73-8	14
312	Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. 2008 , 112, 2267-73	125
311	A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. 2008 , 113, 3420-9	27
310	Canstatin gene electrotransfer combined with radiotherapy: preclinical trials for cancer treatment. 2008 , 15, 1436-45	11
309	Targeted therapy in the treatment of solid tumors: practice contradicts theory. 2008 , 73, 605-18	30
308	Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. 2008 , 99, 1564-71	41
307	Advances in the treatment of breast cancer. 2008 , 83, 26-36	89
306	A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 2008 , 18, 400-6	35
305	Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer. 2008 , 8 Suppl 4, S151-6	9
304	The medical treatment of inflammatory breast cancer. <i>Seminars in Oncology</i> , 2008 , 35, 64-71	5.5 27

303	Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008. 2008 , 8, 313-321	
302	Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. 2008 , 8, 215-23	24
301	Evolution of bevacizumab-based therapy in the management of breast cancer. 2008 , 8, 402-10	26
300	Novel therapies in breast cancer: what is new from ASCO 2008. 2008 , 1, 16	19
299	Review of bevacizumab in the treatment of metastatic breast cancer. 2008 , 6, 13-18	1
298	VEGF and angiogenesis: implications for breast cancer therapy. 2008 , 6, 7-13	14
297	Clinical data for anti-angiogenic agents in previously treated advanced breast cancer. 2008 , 6, 14-20	
296	Bevacizumab in the first-line treatment of metastatic breast cancer. 2008 , 6, 21-28	8
295	Management of toxicity in patients receiving therapy with bevacizumab. 2008 , 6, 29-39	10
294	State of the art therapy for HER2-negative metastatic breast cancer. 2008 , 6, 10-15	1
293	The role of bevacizumab in breast cancer. 2008 , 6, 26-29	2
292	Molecular targeted therapies for breast cancer treatment. 2008 , 10, 211	48
291	Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. 2008 , 10, 511-20	48
290	Thérapeutiques antiangiogéniques en cancérologie. 2008 ,	
289	Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?. 2008 , 40, 565-75	20
288	The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. 2008 , 44, 912-20	50
287	Development of therapeutic approaches to 'triple negative' phenotype breast cancer. 2008 , 12, 1123-37	16
286	Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directions. 2008 , 8, 221-34	6

285	Cardiovascular complications associated with biological therapies for breast cancer. 2008 , 8, 1551-9	5
284	The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. 2008 , 31, 809-19	87
283	Breast Cancer. 2008 ,	3
282	Angiogenesis. 2008 ,	25
281	Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. 2008 , 13, 373-81	25
280	Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206. 2008 , 7, 1547-54	19
279	Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. 2008 , 20, 632-9	53
278	Bevacizumab in the treatment of breast cancer. 2008 , 8, 1559-68	18
277	Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. 2008 , 14, 961-70	36
276	Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. 2008 , 26, 1810-6	421
275	VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. 2008 , 14, 7871-7	115
274	A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. 2008 , 14, 7878-83	95
273	Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. 2008 , 26, 1346-54	123
272	Paclitaxel plus bevacizumab for metastatic breast cancer. 2008 , 358, 1637; author reply 1637-8	12
271	Emerging drugs for diabetic retinopathy. 2008 , 13, 675-94	22
270	Chapter 20. 2008 , 403-422	
269	Targeted therapies in breast cancer: established drugs and recent developments. 2008 , 3, 85-98	22
268	Bevacizumab for refractory solid tumors in pediatric patients. 2008 , 2, 147-149	

267	Transcatheter Arterial Chemoembolization: Technique and Future Potential. 192-201		1
266	New Concepts in Targeting and Imaging Liver Cancer. 202-212		
265	Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. 2008 , 19, 427-9		18
264	Bevacizumab in the treatment of HER2-negative breast cancer. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 813-21	4-4	5
263	Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. <i>OncoTargets and Therapy</i> , 2008 , 1	4-4	
262	First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab. 2009 , 1, CMT.S1981		
261	The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. 2009 , 100, 971-8		89
260	The use of endostatin in the treatment of solid tumors. 2009 , 9, 641-8		16
259	The future of targeted therapies in ovarian cancer. 2009 , 14, 706-16		45
258	Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies. 2009 , 4, 46-50		
257	Immunological Approaches in the Treatment of Metastasized Breast Cancer. 2009 , 4, 359-366		10
256	Managing adverse events in the use of bevacizumab and chemotherapy. 2009 , 18, 351-6, 358		11
255	Adverse events in bevacizumab and chemotherapy: patient management. 2009 , 18, 424-8		9
254	Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine. 2009 , 9, 777-88		17
253	Bevacizumab and breast cancer: current therapeutic progress and future perspectives. 2009 , 9, 1715-25		16
252	Emerging drugs in metastatic breast cancer. 2009 , 14, 85-98		5
251	Bevacizumab: current indications and future development for management of solid tumors. 2009 , 9, 507-17		56
250	Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. 2009 , 27, 11-5		133

249	Understanding and managing the possible adverse effects associated with bevacizumab. 2009 , 66, 999-1013	76
248	A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. 2009 , 15, 3583-90	84
247	Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab. 2009 , 43, 1370-3	11
246	Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study. 2009 , 9, 338	6
245	Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer. 2009 , 18, 66-8	5
244	Cancers gynécologiques. 2009 , 11, 373-376	
243	Treatment of metastatic breast cancer: looking towards the future. 2009 , 114, 413-22	30
242	A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. 2009 , 27, 565-70	15
241	Tumoral angiogenesis and breast cancer. 2009 , 11, 138-42	27
240	Targeted therapy of metastatic breast cancer. 2009 , 11, 643-50	27
239	Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. 2009 , 4, 67-76	25
238	The role of vascular endothelial growth factor genetic variability in cancer. 2009 , 15, 5297-302	66
237	Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. 2009 , 53, 2231-47	885
236	Antiangiogenic therapy for metastatic breast cancer: current status and future directions. 2009 , 69, 167-81	12
235	Safety of Bevacizumab in Advanced Ovarian and Mllarian Cancers: A Review. 2009 , 2, 31-37	0
234	Breast Cancer in the Post-Genomic Era. 2009 ,	3
233	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. 2009 , 50, 728-35	71
232	Promising molecular targets in ovarian cancer. 2009 , 21, 412-9	20

231	Editorial. 2009 , 20 Spec No 1, S1-3	86
230	Anti-angiogenic therapy: from laboratory to the patient. 2009 , 12,	
229	The discovery of antiangiogenic molecules: a historical review. 2009 , 15, 345-52	36
228	Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. 2010 , 11, 861-8	36
227	Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension. 2010 , 19, 169-76	15
226	Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features. 2010 , 26, 137-43	7
225	Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. 2010 , 13, 43-58	89
224	Antiangiogenesis Therapy in Breast Cancer. 2010 , 2, 4-15	1
223	The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer. 2010 , 12, 22-5	5
222	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. 2010 , 121, 121-31	172
221	Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. 2010 , 123, 463-9	39
220	Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety. 2010 , 10, 119-29	16
219	Antiangiogenic therapies in early-stage breast cancer. 2010 , 10 Suppl 1, E23-31	13
218	GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. 2010 , 10, 397	29
217	The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. 2010 , 118, 167-71	44
216	Antiangiogenic strategies in breast cancer management. 2010 , 76, 13-35	16
215	Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. 2010 , 2, 37-44	4
214	Regulation of tumor angiogenesis by the local environment. 2010 , 15, 195-212	31

213	Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. 2010 , 28, 3239-47	711
212	Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?. 2010 , 2, 331-42	5
211	A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. 2010 , 21, 370-375	52
210	Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. 2010 , 28, 628-33	41
209	Biology and management of inflammatory breast cancer. 2010 , 10, 209-20	10
208	A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. 2010 , 15, 810-8	52
207	Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. 2010 , 16, 311-9	144
206	Bevacizumab for advanced breast cancer. 2010 , 6, 17-25	4
205	Safety profile of new anticancer drugs. 2010 , 9, 301-17	15
204	PDGF and vessel maturation. 2010 , 180, 103-14	183
203	Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. 2010 , 7, 1159-73	28
202	Present and future evolution of advanced breast cancer therapy. 2010 , 12 Suppl 2, S1	40
201	Antiangiogenic therapy for breast cancer. 2010 , 12, 209	17
200	Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. 2010 , 10 Suppl 2, S30-40	
199	Clinical overview of sorafenib in breast cancer. 2010 , 6, 655-63	19
198	Emerging targeted therapies for breast cancer. 2010 , 28, 3366-79	148
197	Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. 2010 , 46, 901-11	45
196	Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. 2010 , 46, 3022-36	28

195	Bevacizumab treatment for advanced breast cancer. 2011 , 16, 1684-97		15
194	Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure?. 2011 , 7, 807-10		3
193	Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. 2011 , 53, 115-29		16
192	The role of targeted therapy in ovarian cancer. 2011 , 47 Suppl 3, S116-30		41
191	In pursuit of new anti-angiogenic therapies for cancer treatment. 2011 , 16, 803-14		15
190	Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. 2011 , 9, 403-7		96
189	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. 2011 , 30, 3222-33		155
188	"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. <i>Seminars in Oncology</i> , 2011 , 38, 254-62	5.5	18
187	Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 2011 , 20, 176-83		36
186	Normalization of the vasculature for treatment of cancer and other diseases. 2011 , 91, 1071-121		1040
185	Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. 2011 , 29, 182-8		18
184	Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. 2011 , 14, 155-61		27
183	Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. 2011 , 13, 710-4		29
182	Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab. 2011 , 79, 408-13		19
181	Anti-angiogenic therapy in uveal melanoma. 2012 , 49, 117-136		21
180	Individualisierte Therapie des Mammakarzinoms. 2011 , 8, 196-202		
179	[Individualized treatment of breast cancer]. 2011 , 136, 486-91		2
178	Bevacizumab treatment for solid tumors: boon or bust?. 2011 , 305, 506-8		45

177	Bird's Eye View on the Recent Advances in Drug Delivery Systems. 2011 , 02, 544-556	3
176	Handbook of Metastatic Breast Cancer. 2011 ,	
175	Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer. 2011 , 5, 239-46	1
174	Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?. 2011 , 29, 603-6	26
173	Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. 2011 , 17, 7634-44	58
172	Safety of bevacizumab in patients with metastatic breast cancer. 2011 , 80, 314-25	19
171	Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. 2011 , 286, 13626-37	39
170	Taming glioblastoma by targeting angiogenesis: 3 years later. 2011 , 29, 124-6	22
169	Bevacizumab in metastatic breast cancer: when may it be used?. 2011 , 3, 85-93	9
168	A Review of the Treatment Options in Recurrent Glioblastoma: Focus on Bevacizumab. 2011 , 3, 79-92	
167	Targeting angiogenesis in metastatic breast cancer. 2012 , 17, 1014-26	19
166	Personalizing cardiovascular disease prevention among breast cancer survivors. 2012 , 27, 515-24	13
165	Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. 2012 , 18, 6040-8	28
164	Target-based anti-angiogenic therapy in breast cancer. 2012 , 18, 4244-57	32
163	Sorafenib in locally advanced or metastatic breast cancer. 2012 , 21, 1177-91	18
162	Bevacizumab in endometrial cancer treatment. 2012 , 12, 649-58	14
161	Anti-VEGF therapies in the clinic. 2012 , 2,	155
160	Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. 2012 , 17, 469-75	39

159	Trials of bevacizumab in breast cancer--a safety review. 2012 , 11 Suppl 1, S37-48	5
158	Combination drug delivery approaches in metastatic breast cancer. 2012 , 2012, 915375	89
157	Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer. 2012 , 18, 2680-701	18
156	Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome. 2012 , 7, 265-288	4
155	[Targeted therapy and breast cancer: state of the art]. 2012 , 60, 254-63	2
154	Phase II open-label study of sunitinib in patients with advanced breast cancer. 2012 , 136, 759-67	19
153	North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. 2012 , 12, 387-91	15
152	Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. 2012 , 82, 58-66	61
151	Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. 2012 , 138, 1845-52	3
150	Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. 2012 , 23, 1130-1137	54
149	A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. 2012 , 5, 17	1
148	Benefit-risk assessment of bevacizumab in the treatment of breast cancer. 2012 , 35, 15-25	7
147	A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia. 2012 , 125, 828-30	11
146	Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. 2012 , 38, 673-88	85
145	Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. 2012 , 12, 620	13
144	Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question. 2012 , 6, 70-7	3
143	An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. 2012 , 118, 4098-104	23
142	Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. 2012 , 30, 1756-60	6

141	Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?. 2012 , 13, 249-62	10
140	A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. 2012 , 134, 13-20	41
139	Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. 2012 , 21, 82-91	270
138	Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model. 2012 , 3, 229-238	13
137	Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. 2012 , 103, 626-31	61
136	Bevacizumab in the treatment of metastatic breast cancer: friend or foe?. 2012 , 14, 1-11	64
135	Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. 2012 , 30, 681-7	35
134	A phase 3 trial comparing capecitabine in combination with Sorafenib or placebo for treatment of locally advanced or metastatic HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. 2013 , 14, 228	29
133	[Cardiotoxicity of chemotherapies]. 2013 , 42, 26-39	11
132	The Future of Chemotherapy in the Era of Personalized Medicine. 2013 , 5, 57-68	2
131	MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response. 2013 , 61, 285-99	21
130	The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?. 2013 , 2, 202	2
129	A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. 2013 , 18, 590-7	7
128	Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. 2013 , 301, 1-35	70
127	Rolle der Angiogenese und ihrer Inhibitoren in der Gynäkologie. 2013 , 46, 56-62	2
126	Targeted anti-vascular therapies for ovarian cancer: current evidence. 2013 , 108, 250-8	58
125	A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. 2013 , 49, 312-22	72
124	Antiangiogenic effects of marine sponge derived compounds on cancer. 2013 , 36, 1097-108	12

123	Novel strategies towards the use of anti-angiogenic agents in breast cancer. 2013 , 717, 36-9	4
122	Intravitreal bevacizumab for ocular metastasis of multiple myeloma. 2013 , 90, e236-40; discussion 1028	10
121	The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. 2013 , 73, 5618-24	100
120	Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. 2013 , 19, 2745-54	60
119	More sound cancer therapy biomarker development with active noise control. 2013 , 18, 239-41	1
118	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. 2013 , 105, 1441-56	41
117	Optimal Biological Dose for Molecularly Targeted Therapies. 2014 , 496-505	
116	Optimal Biological Dose for Molecularly-Targeted Therapies. 2014 ,	
115	Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment. 2014 , 21, 293-301	9
114	Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. 2014 , 14, 820	142
113	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. 2014 , 10, 1137-45	16
112	Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth. 2014 , 307, C14-24	20
111	Suppression of angiogenesis and tumor growth and using an anti-angiopoietin-2 single-chain antibody. <i>Experimental and Therapeutic Medicine</i> , 2014 , 7, 543-552	2.1 12
110	Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer. 2014 , 37, 480-5	14
109	Metabolic tumor profiling with pH, oxygen, and glucose chemosensors on a quantum dot scaffold. 2014 , 53, 1900-15	51
108	Bevacizumab: a review of its use in advanced cancer. 2014 , 74, 1891-1925	119
107	Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). 2015 , 3, 519-43	13
106	Contrast-enhanced ultrasound with perflubutane in the assessment of anti-angiogenic effects: early prediction of the anticancer activity of bevacizumab in a mouse xenografted model. 2015 , 41, 2497-505	2

105	Bevacizumab: A dose review. 2015 , 94, 311-22	24
104	Targeting the tumor vasculature to enhance T cell activity. 2015 , 33, 55-63	169
103	Targeted Therapies in Triple-Negative Breast Cancer. 2015 , 10, 159-66	44
102	A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. 2015 , 11, 1368-86	14
101	Current opinion on bevacizumab on endometrial cancer treatment. 2015 , 15, 299-307	6
100	Use of bevacizumab in recurrent glioblastoma. 2015 , 4, 157-69	21
99	Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. 2015 , 21, 1851-8	51
98	Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. 2015 , 38, 74-9	14
97	Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'-deoxy-3'-fluoro-L-thymidine positron emission tomography/computed tomography. 2015 , 76, 187-95	9
96	Multifunctional Polymeric Nano-Carriers in Targeted Drug Delivery. 2015 , 461-500	3
95	Hypoxia and angiogenesis: from primary tumor to bone metastasis. 2015 , 177-189	1
94	Pharmaceutical Biotechnology. 2016 ,	5
93	Optimal Biological Dose for Molecularly Targeted Therapies. 2016 , 1-12	
92	Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. 2016 , 11, e0160148	8
91	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). 2016 , 34, 2602-9	77
90	Population pharmacokinetics of bevacizumab in cancer patients with external validation. 2016 , 78, 341-51	33
89	Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. 2016 , 10, 704-18	34
88	Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy. 2016 , 22, 1611-20	22

87	Ten years of anti-vascular endothelial growth factor therapy. 2016 , 15, 385-403	507
86	Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer. 2017 , 24, 147-151	4
85	Targeting the Breast Cancer Kinome. 2017 , 232, 53-60	16
84	Strategies to design clinical studies to identify predictive biomarkers in cancer research. 2017 , 53, 79-97	64
83	Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. 2017 , 17, 497-506	4
82	Vessel pruning or healing: endothelial metabolism as a novel target?. 2017 , 21, 239-247	31
81	Cardio-Oncology. 2017 ,	1
80	Treatment of Hypertension in Patients Receiving Cancer Therapy. 2017 , 105-123	1
79	Bevacizumab Therapy for Pilocyctic Astrocytoma. 2017 , 39, e219-e223	1
78	A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers. 2017 , 5, e00286	16
77	Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer. <i>Seminars in Oncology</i> , 2017 , 44, 273-285	5.5 11
76	Targeting Oncoproteins for Molecular Cancer Therapy. 2017 , 727-756	
75	Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. 2017 , 9, e1258	5
74	An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs. 2017 , 22,	113
73	Recent Advances in Angiogenesis Assessment Methods and their Clinical Applications. 2017 ,	1
72	The dark side of tumor-associated endothelial cells. 2018 , 35, 35-47	50
71	Combinational drug delivery using nanocarriers for breast cancer treatments: A review. 2018 , 106, 2272-2283	28
70	Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer. 2018 , 9, 613-620	

69	First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. 2018 , 24, 1536-1545 ⁴⁹	
68	Tanshinone II A improves distribution and anti-tumor efficacy of pegylated liposomal doxorubicin via normalizing the structure and function of tumor vasculature in hepa1-6 hepatoma mice model. 2018 , 38, 815-822	2
67	Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model. 2018 , 8, 15837	15
66	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. 2018 , 172, 93-104	14
65	Anterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti-angiogenic treatment. 2018 , 16, 3083-3091	8
64	Breast Cancer Metastasis and Drug Resistance. 2019 ,	13
63	Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology. 2019 , 5, 106-111	17
62	Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells. 2019 , 82, 38-44	1
61	Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. 2019 , 45, 22-28	4
60	Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. 2019 , 37, 331-337	11
59	Designing clinical studies for biomarker discovery: The Design criteria. 2020 , 441-466	
58	Microenvironmental Heterogeneity Among Triple-Negative Breast Cancer Subtypes and the Promise of Precision Medicine. 2020 , 112, 661-662	
57	Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study. 2020 , 30, 102-106	2
56	B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. 2020 , 16, 1767-1791	5
55	Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer. 2021 ,	5
54	A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. 2021 , 88, 465-474	0
53	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. 2021 , 7, 110	5
52	Angiogenesis inhibitors: what is the clinical future?. 2005 , 63, 67-91	1

51	The Clinical Utility of Bevacizumab. 2008 , 375-385	2
50	VEGF Inhibition for Cancer Therapy. 2008 , 573-584	1
49	Therapeutic Options for Metastatic Breast Cancer. 2019 , 1152, 131-172	14
48	The Value of Antiangiogenics in Breast Cancer Therapy. 2017 , 1-13	1
47	Tyrosine kinase inhibitors and cancer therapy. 2007 , 172, 25-44	4
46	Cancer of the Breast. 2008 , 1875-1943	8
45	The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. 2018 , 9, 14619-14629	10
44	Angiogenesis in cancer. 2006 , 2, 213-9	772
43	Chemotherapy and metastatic breast cancer. 2006 , 41-68	1
42	Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium. 2010 , 2, 160-70	22
41	Antiangiogenic mechanisms and factors in breast cancer treatment. 2016 , 15, 1	30
40	Antiangiogenic Agents in Breast Cancer. 2007 , 269-284	
39	Survivin. 2007 , 209-218	
38	Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside. 2008 , 323-330	2
37	Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease. 2008 , 63-80	
36	Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy. 2009 , 203-224	
35	Chemotherapy for Metastatic Breast Cancer. 2009 , 1233-1261	1
34	Targeted Therapy for Breast Cancer: A Focus on HER2/neu and Antiangiogenic Therapy. 2009 , 513-521	

- 33 Biological therapy of breast cancer. **2009**, 669-678
- 32 Safety of Bevacizumab in Advanced Ovarian and Mlllerian Cancers: A Review. **2009**, 3, E7-E13
- 31 Chemotherapeutic Agents. **2010**, 353-372
- 30 VALUE INTERCELLULAR interactions, extracellular matrix and vascular FACTOR IN THE DEVELOPMENT OF BREAST TUMORS. **2010**, 18, 163
- 29 Targeting angiogenesis in metastatic breast cancer. **2011**, 101-119
- 28 Monoclonal Antibodies. *Cancer Drug Discovery and Development*, **2014**, 585-624 0.3
- 27 Heart, Coronary Arteries, Aorta and Great Vessels, Arteries and Veins, Microcirculation. *Medical Radiology*, **2014**, 287-323 0.2
- 26 Angiogenesis Inhibitors in the Treatment of Breast Cancer: Exploring Avenues of New Therapeutic Targets. *Journal of Cancer Prevention & Current Research*, **2015**, 2, 1.3
- 25 Systemic Therapy. **2016**, 335-390
- 24 Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. **2017**, 1-31
- 23 The Value of Anti-angiogenics in Breast Cancer Therapy. **2019**, 515-527
- 22 Angiogenesis Inhibition in Breast Cancer. **2019**, 507-528
- 21 Cardio-Oncology. **2020**, 447-452
- 20 Evidence-Based Management of Breast Cancer. **2006**, 960-991 1
- 19 Experimentelle Therapie und somatische Genthherapie von Krebs. **2005**, 258-267
- 18 Targeted Therapy For Breast Cancer. **2008**, 309-342
- 17 Antibody Therapy of Cancer. **2008**, 371-412
- 16 Targeted Therapy in Breast Cancer. **2008**, 43-59

15	Bon usage des antiangiogéniques: le point de vue du pharmacien. 2008 , 53-65		
14	Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis. 2006 , 671-704		
13	Experimentelle Therapie und somatische Gentherapie von Krebs. 2007 , 292-301		
12	Rationale for combining biotherapy in the treatment of advanced colon cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 145-51		3
11	First line targeted therapies in breast cancer: focus on bevacizumab. <i>Biologics: Targets and Therapy</i> , 2007 , 1, 3-10	4.4	2
10	Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. <i>OncoTargets and Therapy</i> , 2009 , 2, 1-15	4.4	8
9	Bevacizumab and intraocular tumors: an intriguing paradox. <i>Molecular Vision</i> , 2012 , 18, 2454-67	2.3	21
8	Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2021 , 22, 1463	2.1	1
7	Modulation of Tumor Vasculature Network: Key Strategies. <i>Small Structures</i> , 2100164	8.7	1
6	Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. 2022 , 7, 100576		0
5	Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report. 2022 , 25,		0
4	Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future. 2023 , 73-98		0
3	Hypoxia signaling in cancer: Implications for therapeutic interventions. 2023 , 4,		1
2	Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity. 2023 , 24, 4422		0
1	A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. 13,		0